Ad5F35-LMP2重组腺病毒修饰DC体内特异性抗瘤作用的研究

目的 了解含有EB病毒潜伏膜蛋白2的非复制型重组腺病毒（Ad5F35-LMP2）修饰的DC能否在体内抑制肿瘤细胞生长.方法 人外周血单个核细胞在细胞因子IL-4、GM-CSF和TNF-a诱导下生成树突状细胞.将人的外周血单个核细胞移植入实验组SCID小鼠体内2次,再分别经两次DC与Ad5F35-LMP2-DC免疫SCID小鼠,然后用1×10^6的CNE-2肿瘤细胞接种SCID小鼠皮下,观察肿瘤生长情况.结果 Ad5F35-LMP2-DC组肿瘤的潜伏期明显延长,对照组和DC组小鼠1周左右就出现了肿瘤,而Ad5F35-LMP2-DC组则直到2周左右才出现肿瘤;且肿瘤体积最小,重量最轻,与DC组比Ad5F35-LMP2-DC疫苗组的肿瘤抑制率为64.75%.结论 Ad5F35-LMP2重组腺病毒疫苗修饰的DC在体内可以有效的抑制NPC肿瘤细胞CNE-2生长.

Tumor suppression in vivo of DC vaccine modified by recombinant adenovirus Ad5F35-LMP2

Objective To observe whether dendritic cells(DCs) transfected with recombinant adenovirus Ad5F35-LMP2 suppress the proliferation of CNE-2 in vivo. Methods Dendritic cells have been generated with the induction of IL-4,GM-CSF and TNF-a in vitro. After human PBMCs were transplant into SCID mice,SCID mice were vaccinated with Ad5F35-LMP2-DC or untransfected DC. And four days latter,CNE-2 (1×106cell for each mouse) inoculated into SCID mouse subcutaneously. The tumor growth was monitored every week. Results The tumor latent period of Ad5F35-LMP2-DC group is longer among three groups. Untransfected DC group and CNE-2 positive control group could be found tumor about one week, but Ad5F35-LMP2-DC group was about two weeks. And the tumor was smaller and lighter than untransfected DC group and CNE-2 positive control group. Average tumor control rate reached 64.75% compared with untransfected DC group. Conclusion Ad5F35-LMP2-DC could effectively suppress the proliferation of CNE2 in vivo.